• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非甾体抗炎药在术后眼部炎症管理中的作用。

The role of NSAIDs in the management of postoperative ophthalmic inflammation.

作者信息

Colin Joseph

机构信息

University Hospital Complex of Bordeaux, Peflegrin Hospital, Bordeaux, France.

出版信息

Drugs. 2007;67(9):1291-308. doi: 10.2165/00003495-200767090-00004.

DOI:10.2165/00003495-200767090-00004
PMID:17547472
Abstract

Recent advances in cataract surgery, such as phacoemulsification, small-incision surgery and advances in foldable intraocular lenses, have resulted in the decrease of physical trauma associated with cataract surgery. The decrease in the physical surgical trauma decreases the release of prostaglandins, which are the main players in postoperative ocular inflammation. However, postoperative inflammation continues to be a cause of patient discomfort, delayed recovery and, in some cases, suboptimal visual results. Left untreated, this inflammation might interfere with patients' rehabilitation and/or contribute to the development of other complications, such as cystoid macular oedema.NSAIDs are commercially available, in topical or systemic formulations, for the prophylaxis and treatment of ocular conditions. Topically applied NSAIDs are commonly used in the management and prevention of non-infectious ocular inflammation and cystoid macular oedema following cataract surgery. They are also used in the management of pain following refractive surgery and in the treatment of allergic conjunctivitis. Despite their chemical heterogeneity, all NSAIDs share the similar therapeutic property of inhibiting the cyclo-oxygenase enzyme. The appeal of using NSAIDs in the treatment of ocular inflammation hinges on the complications associated with corticosteroids, the other commonly used therapy for ophthalmic inflammation.

摘要

白内障手术的最新进展,如超声乳化术、小切口手术以及可折叠人工晶状体的进步,已使白内障手术相关的身体创伤有所减少。手术身体创伤的减少降低了前列腺素的释放,而前列腺素是术后眼部炎症的主要引发因素。然而,术后炎症仍是导致患者不适、恢复延迟,且在某些情况下导致视觉效果欠佳的一个原因。若不加以治疗,这种炎症可能会干扰患者的康复和/或促使其他并发症的发生,如黄斑囊样水肿。非甾体抗炎药有局部或全身用药的剂型,可用于预防和治疗眼部疾病。局部应用的非甾体抗炎药常用于白内障手术后非感染性眼部炎症和黄斑囊样水肿的管理与预防。它们也用于屈光手术后疼痛的管理以及过敏性结膜炎的治疗。尽管非甾体抗炎药化学性质各异,但它们都具有抑制环氧化酶的相似治疗特性。在治疗眼部炎症时使用非甾体抗炎药的吸引力在于与另一种常用于眼部炎症治疗的药物——皮质类固醇相关的并发症。

相似文献

1
The role of NSAIDs in the management of postoperative ophthalmic inflammation.非甾体抗炎药在术后眼部炎症管理中的作用。
Drugs. 2007;67(9):1291-308. doi: 10.2165/00003495-200767090-00004.
2
Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops: a systematic review.白内障术后预防炎症和黄斑水肿的甾体和非甾体抗炎滴眼液:系统评价。
Ophthalmology. 2014 Oct;121(10):1915-24. doi: 10.1016/j.ophtha.2014.04.035. Epub 2014 Jun 14.
3
Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care.关于使用非甾体抗炎药治疗以优化白内障手术患者护理的新兴指南。
Curr Med Res Opin. 2005 Jul;21(7):1131-7. doi: 10.1185/030079905X50651.
4
Cyclo-oxygenase inhibitors in ophthalmology.眼科中的环氧化酶抑制剂
Surv Ophthalmol. 1992 Jan-Feb;36(4):259-84. doi: 10.1016/0039-6257(92)90095-b.
5
Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery.用于治疗白内障手术后黄斑囊样水肿的非甾体类抗炎药。
Cochrane Database Syst Rev. 2005 Jan 25(1):CD004239. doi: 10.1002/14651858.CD004239.pub2.
6
Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery.双氯芬酸滴眼液在减轻白内障手术后炎症及黄斑囊样水肿发生率方面的有效性。
J Cataract Refract Surg. 1996;22 Suppl 1:794-9. doi: 10.1016/s0886-3350(96)80164-7.
7
The comparative efficacy and safety of topical non-steroidal anti-inflammatory drugs for the treatment of anterior chamber inflammation after cataract surgery: a systematic review and network meta-analysis.局部用非甾体抗炎药治疗白内障术后前房炎症的比较疗效与安全性:一项系统评价和网状Meta分析
Graefes Arch Clin Exp Ophthalmol. 2017 Apr;255(4):639-649. doi: 10.1007/s00417-017-3599-8. Epub 2017 Jan 27.
8
Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery.溴芬酸钠眼药水对白内障手术后眼部炎症的影响。
Acta Ophthalmol. 2009 May;87(3):300-5. doi: 10.1111/j.1755-3768.2008.01433.x. Epub 2009 Jan 31.
9
[Progresses in antiinflamatory treatment in cataract surgery].[白内障手术抗炎治疗的进展]
Oftalmologia. 2011;55(3):89-93.
10
Topical nonsteroidal anti-inflammatory therapy in ophthalmology.眼科局部非甾体抗炎治疗
Ophthalmologica. 2003 Mar-Apr;217(2):89-98. doi: 10.1159/000068563.

引用本文的文献

1
Optimizing pain management and pupil dilation in cataract surgery: a systematic review and meta-analysis of phenylephrine/ketorolac (OMIDRIA®).优化白内障手术中的疼痛管理和瞳孔散大:去氧肾上腺素/酮咯酸(OMIDRIA®)的系统评价和荟萃分析
Graefes Arch Clin Exp Ophthalmol. 2025 Mar 29. doi: 10.1007/s00417-025-06811-y.
2
Cataract Development Among Pediatric Patients With Uveitis.儿童葡萄膜炎患者白内障的发生。
JAMA Netw Open. 2024 Jul 1;7(7):e2419366. doi: 10.1001/jamanetworkopen.2024.19366.
3
Pattern of Preferred Cataract Surgery Practices in Morocco: A Survey-Based Study.

本文引用的文献

1
Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology.局部应用奈帕芬酸可抑制糖尿病诱导的视网膜微血管疾病以及视网膜代谢和生理的潜在异常。
Diabetes. 2007 Feb;56(2):373-9. doi: 10.2337/db05-1621.
2
Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery.0.1%奈帕芬胺眼用混悬液用于预防和治疗与白内障手术相关的眼部炎症。
J Cataract Refract Surg. 2007 Jan;33(1):53-8. doi: 10.1016/j.jcrs.2006.08.043.
3
Comparison of the analgesic efficacy and safety of nepafenac ophthalmic suspension compared with diclofenac ophthalmic solution for ocular pain and photophobia after excimer laser surgery: a phase II, randomized, double-masked trial.
摩洛哥白内障手术偏好模式:一项基于调查的研究。
Cureus. 2024 Mar 6;16(3):e55690. doi: 10.7759/cureus.55690. eCollection 2024 Mar.
4
Ocular Pharmacology and Toxicology of TRPV1 Antagonist SAF312 (Libvatrep).TRPV1 拮抗剂 SAF312(利伐曲班)的眼部药理学和毒理学。
Transl Vis Sci Technol. 2023 Sep 1;12(9):5. doi: 10.1167/tvst.12.9.5.
5
Investigating the associations of macular edema in retinitis pigmentosa.研究色素性视网膜炎黄斑水肿的相关性。
Sci Rep. 2023 Aug 30;13(1):14187. doi: 10.1038/s41598-023-41464-z.
6
Safety of the bag-in-the-lens implantation regarding the development of clinically significant pseudophakic cystoid macular edema: A retrospective case series study.关于袋内透镜植入术引发临床显著的假性囊膜黄斑水肿的安全性:一项回顾性病例系列研究。
PLoS One. 2023 Jan 6;18(1):e0278861. doi: 10.1371/journal.pone.0278861. eCollection 2023.
7
The Immediate Early Response of Lens Epithelial Cells to Lens Injury.晶状体上皮细胞对晶状体损伤的即刻早期反应。
Cells. 2022 Nov 1;11(21):3456. doi: 10.3390/cells11213456.
8
Comparison of once daily dose of 0.3% nepafenac alone and three times dose of 0.1% nepafenac alone in pain and inflammation control after phacoemulsification.白内障超声乳化术后每日一次 0.3% 尼非帕芬和三次 0.1% 尼非帕芬单独使用在疼痛和炎症控制方面的比较。
Indian J Ophthalmol. 2022 Mar;70(3):807-812. doi: 10.4103/ijo.IJO_2401_21.
9
A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease.0.25%局部用瑞普洛芬与5%利非司特在干眼病患者中的急性后眼耐受性比较
Clin Ophthalmol. 2021 Sep 22;15:3889-3900. doi: 10.2147/OPTH.S327691. eCollection 2021.
10
Prednisolone and Ketorolac vs Ketorolac Monotherapy or Sub-Tenon Prophylaxis for Macular Thickening in Cataract Surgery: A Randomized Clinical Trial.泼尼松龙和酮咯酸与酮咯酸单药治疗或术尔泰预防白内障手术中黄斑增厚的比较:一项随机临床试验。
JAMA Ophthalmol. 2021 Oct 1;139(10):1062-1070. doi: 10.1001/jamaophthalmol.2021.2976.
准分子激光手术后眼部疼痛和畏光时,奈帕芬胺眼用混悬液与双氯芬酸眼用溶液镇痛疗效及安全性的比较:一项II期随机双盲试验。
Clin Ther. 2006 Apr;28(4):527-36. doi: 10.1016/j.clinthera.2006.04.004.
4
Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac.眼部渗透与视网膜炎症抑制:关于萘非那酮临床效用的数据及专家意见审视
Curr Med Res Opin. 2006 Feb;22(2):397-404. doi: 10.1185/030079906X89775.
5
Corneal ulceration and perforation with ketorolac tromethamine (Acular) use after PRK.准分子激光原位角膜磨镶术(PRK)后使用酮咯酸氨丁三醇(阿乐迈)导致的角膜溃疡和穿孔。
Cornea. 2006 Feb;25(2):232-4. doi: 10.1097/01.ico.0000179931.05275.dd.
6
Three cases of corneal melting after instillation of a new nonsteroidal anti-inflammatory drug.三例在滴注一种新型非甾体抗炎药后发生角膜溶解的病例。
Cornea. 2006 Feb;25(2):224-7. doi: 10.1097/01.ico.0000177835.93130.d4.
7
Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care.关于使用非甾体抗炎药治疗以优化白内障手术患者护理的新兴指南。
Curr Med Res Opin. 2005 Jul;21(7):1131-7. doi: 10.1185/030079905X50651.
8
The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients.双氯芬酸眼药水对原发性开角型青光眼患者局部使用0.5%噻吗洛尔和0.005%拉坦前列素降眼压效果的影响。
Exp Eye Res. 2005 Nov;81(5):610-5. doi: 10.1016/j.exer.2005.03.020. Epub 2005 Jun 8.
9
Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgery.0.4% 外用酮咯酸氨丁三醇用于控制白内障手术相关疼痛或不适的疗效。
Curr Med Res Opin. 2004 Dec;20(12):2015-9. doi: 10.1185/030079904x16759.
10
Safety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patients.0.4% 酮咯酸氨丁三醇滴眼液在准分子激光原位角膜磨镶术后患者中的安全性和有效性
J Cataract Refract Surg. 2004 Aug;30(8):1653-60. doi: 10.1016/j.jcrs.2004.05.019.